<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549559</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HL141563</org_study_id>
    <nct_id>NCT03549559</nct_id>
  </id_info>
  <brief_title>Imaging Histone Deacetylase in the Heart</brief_title>
  <official_title>Imaging of Histone Deacetylase in the Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone&#xD;
      deacetylase targeted radioligand, in patients with aortic stenosis, individuals with&#xD;
      diabetes, and healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Histone deacetylases (HDACs), a class of epigenetic enzymes, play an important role in the&#xD;
      pathophysiology of heart failure, including development of left ventricular hypertrophy and&#xD;
      myocardial fibrosis. Preclinical data demonstrate the importance of HDAC inhibition in&#xD;
      attenuating these pathological processes and maintaining the integrity of the myocardium.&#xD;
      However, the role of HDACs in the human heart, and the utility of HDAC inhibition remains&#xD;
      unknown. Therefore, a noninvasive method to detect HDAC activity in the human heart in&#xD;
      healthy individuals and patients with heart disease may be of major medical and public health&#xD;
      value to help determine prognosis, direct therapy, and guide the development of novel&#xD;
      therapies for heart failure. The investigators have recently developed a novel radiotracer,&#xD;
      11C-Martinostat, which binds with high affinity to class I HDACs. The objective of this&#xD;
      protocol is to assess the utility of 11C-Martinostat PET-MR to detect HDAC expression in the&#xD;
      hearts of healthy individuals and patients with severe aortic stenosis or diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>11C-Martinostat Binding</measure>
    <time_frame>10-60 minutes post-injection</time_frame>
    <description>Comparison of regional HDAC activity as measured by standard uptake value ratio (SUVR) of 11C-Martinostat between patient subjects with aortic stenosis or diabetes and healthy volunteers</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes Patient Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic Stenosis Patient Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-Martinostat</intervention_name>
    <description>Imaging probe for evaluating the activity of histone deacetylase in the heart</description>
    <arm_group_label>Aortic Stenosis Patient Subjects</arm_group_label>
    <arm_group_label>Diabetes Patient Subjects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET-MRI</intervention_name>
    <description>Siemens PET-MR Scanner (Biograph MMR)</description>
    <arm_group_label>Aortic Stenosis Patient Subjects</arm_group_label>
    <arm_group_label>Diabetes Patient Subjects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1: Healthy Volunteers (n = 30)&#xD;
&#xD;
          -  Healthy adults with no known history of medical disease&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  No history cardiovascular disease&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Group 2: Patients with Diabetes (n = 16)&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  Diagnosis of diabetes&#xD;
&#xD;
          -  Echocardiogram within last 12 months showing no evidence of left ventricular&#xD;
             hypertrophy or hemodynamic findings consistent with heart failure with preserved&#xD;
             ejection fraction&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Group 3: Patients with Aortic Stenosis (n = 50)&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular&#xD;
             hypertrophy and degenerative calcific aortic stenosis&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David E Sosnovik, MD</last_name>
    <phone>617-724-3407</phone>
    <email>dsosnovik@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne L Philip, MPH</last_name>
    <phone>617-726-0431</phone>
    <email>alphilip@mgh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David E Sosnovik</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

